TY - JOUR
T1 - Bile acid profiles in neonatal intrahepatic cholestasis caused by citrin deficiency
AU - Yang, Ching Hsuan
AU - Chen, Chiung Yu
AU - Chou, Yen Yin
AU - Chiu, Hung Chih
AU - Tsai, Wei Lun
AU - Shiesh, Shu Chu
N1 - Publisher Copyright:
© 2017 Elsevier B.V.
PY - 2017/12
Y1 - 2017/12
N2 - Background Neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD) is characterized by conjugated hyperbilirubinemia and increased plasma bile acid concentrations. However, the underlying mechanisms remain unclear. We established a liquid chromatography tandem mass spectrometry (LC-MS/MS) method for simultaneously quantifying plasma bile acids and examined bile acid profiles in NICCD infants. Methods We measured 15 bile acids within 15 min and found a wide linear range for individual bile acids. Results The within-run and run-to-run CV of all bile acids was 1.2–10.9% and 3.1–10.8%, respectively, with a mean recovery of 90.5–112.6%. Compared to infants with citrullinemia without mutations in SLC25A13 (non-NICCD), NICCD infants showed increased plasma total bile acid concentrations (mean: 201 vs. 42 μM, p < 0.001), with a distinct bile acid profile characterized by increased conjugated primary bile acid concentrations. The calculated ratios, including primary/secondary bile acid (714 vs. 235, p < 0.05) and conjugated/free bile acid (371 vs. 125, p < 0.05) ratios, were higher in NICCD infants. The area under receiver operating characteristic curve for conjugated/free bile acid ratio to identify infants with NICCD was 0.871 (95% confidence interval, 0.713–1.0). Conclusions Together, our findings indicated plasma bile acid profile as a potential noninvasive diagnostic biomarker for NICCD.
AB - Background Neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD) is characterized by conjugated hyperbilirubinemia and increased plasma bile acid concentrations. However, the underlying mechanisms remain unclear. We established a liquid chromatography tandem mass spectrometry (LC-MS/MS) method for simultaneously quantifying plasma bile acids and examined bile acid profiles in NICCD infants. Methods We measured 15 bile acids within 15 min and found a wide linear range for individual bile acids. Results The within-run and run-to-run CV of all bile acids was 1.2–10.9% and 3.1–10.8%, respectively, with a mean recovery of 90.5–112.6%. Compared to infants with citrullinemia without mutations in SLC25A13 (non-NICCD), NICCD infants showed increased plasma total bile acid concentrations (mean: 201 vs. 42 μM, p < 0.001), with a distinct bile acid profile characterized by increased conjugated primary bile acid concentrations. The calculated ratios, including primary/secondary bile acid (714 vs. 235, p < 0.05) and conjugated/free bile acid (371 vs. 125, p < 0.05) ratios, were higher in NICCD infants. The area under receiver operating characteristic curve for conjugated/free bile acid ratio to identify infants with NICCD was 0.871 (95% confidence interval, 0.713–1.0). Conclusions Together, our findings indicated plasma bile acid profile as a potential noninvasive diagnostic biomarker for NICCD.
UR - http://www.scopus.com/inward/record.url?scp=85030751856&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030751856&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2017.10.005
DO - 10.1016/j.cca.2017.10.005
M3 - Article
C2 - 28987776
AN - SCOPUS:85030751856
SN - 0009-8981
VL - 475
SP - 28
EP - 35
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
ER -